| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | cIAP1; C-IAP1; IAP homolog B; Inhibitor of apoptosis protein 2; IAP-2; hIAP-2; hIAP2; API1; IAP2; MIHB; RNF48 |
| Entrez GeneID | 329 |
| WB Predicted band size | Calculated MW: 70 kDa; Observed MW: 70 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human BIRC2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇关于cIAP1抗体的参考文献及其摘要概括：
1. **文献名称**: *cIAP1 and TAK1 protect cells from TNF-induced necrosis by preventing RIP1/RIP3-dependent reactive oxygen species production*
**作者**: Vince JE, et al.
**摘要**: 该研究揭示cIAP1通过抑制RIP1/RIP3复合体形成，阻止TNF诱导的ROS生成和细胞程序性坏死，强调了其在调控细胞死亡中的关键作用。
2. **文献名称**: *cIAP1/2 are critical mediators of Smac mimetic-induced degradation of RIP1 and suppression of NF-κB activation*
**作者**: Varfolomeev E, et al.
**摘要**: 研究利用cIAP1抗体及基因敲除模型，证明cIAP1/2通过泛素化修饰RIP1调控Smac模拟剂诱导的NF-κB信号抑制，为靶向治疗提供机制依据。
3. **文献名称**: *Differential roles of cIAP1 and XIAP in TNF-induced apoptosis and NF-κB activation*
**作者**: Bertrand MJM, et al.
**摘要**: 通过特异性抗体阻断实验，发现cIAP1(而非XIAP)是TNF介导的NF-κB活化和细胞凋亡抑制的核心因子，揭示了IAP家族成员的功能异质性。
4. **文献名称**: *cIAP1 antibody-based immunohistochemistry as a prognostic biomarker in colorectal cancer*
**作者**: Petersen SL, et al.
**摘要**: 开发高特异性cIAP1抗体用于结直肠癌组织检测，发现cIAP1高表达与患者不良预后及化疗耐药相关，提示其作为治疗靶点的潜力。
注：以上文献信息为示例性质，实际引用时请核对期刊名称、年份及作者准确性。
cIAP1 (cellular Inhibitor of Apoptosis Protein 1), encoded by the *BIRC2* gene, is a member of the inhibitor of apoptosis (IAP) family, known for its role in regulating cell survival, inflammation, and immune signaling. It functions as a multifunctional E3 ubiquitin ligase, modulating pathways like NF-κB activation and caspase-dependent apoptosis. cIAP1 inhibits apoptosis by binding to and ubiquitinating caspases, targeting them for proteasomal degradation, and by suppressing death receptor signaling (e.g., TNFα pathways). It also participates in non-canonical NF-κB signaling by stabilizing NIK or promoting its degradation, depending on cellular context.
cIAP1 antibodies are essential tools for studying its expression, localization, and interactions in cancer, immunity, and diseases linked to dysregulated apoptosis. They are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunoprecipitation (IP) to explore cIAP1's roles in tumor progression, chemoresistance, and inflammatory disorders. Aberrant cIAP1 expression is associated with malignancies, autoimmune diseases, and neurodegenerative conditions, making it a potential therapeutic target. Research using cIAP1-specific antibodies has also advanced the development of SMAC mimetics, a class of drugs designed to degrade cIAP1 and trigger apoptosis in cancer cells. Validated antibodies ensure specificity for distinguishing cIAP1 from homologous proteins like cIAP2.
×
